Medina GE, Rubio GAF, Vargas AG, Rivera HX

Language: Spanish
References: 21
Page: 568-572
PDF size: 388.38 Kb.

ABSTRACT

Objective: To compare peripheral arterial disease (PAD) in type 2 diabetic patients who also suffer from hypertension.
Material and Methods: We compared the ankle-brachial index (ABI) of diabetic patients with diabetic and hypertensive patients. We excluded patients in whom technical issues can’t adequately take the ABI or who have high risk for PAD (eg heavy smoking). ABI was measured and laboratory studies at the time of recruitment.
Results: 50 patients, 25 in each group. The mean age was 53.68 years in the diabetes mellitus tipo 2 group and 45.04 years for DM2/ Hypertension, except in the genus groups were homogeneous. The biochemical variables were similar. We obtained an ABI of 1.02 in the DM2 group and 1.07 in that of DM2/Hypertension with p = 0.25. Whereas an ABI = ‹0.9 and PAD was obtained 2.82 with a 95% 0.44- 12.44, p = 0.16; By comparing =› 1.3, There were 4 patients (15.38%) in the DM2/HAS group and none in group DM2 [OR 10.6, with 95% CI 0.54 - 207.7, P = 0.11]
Discussion: hypertension increases the risk of PAD in patients with DM2. Since the ABI =› 1.3 is observed in 16% of patients with hypertension and in 0% without further studies should be made only for this purpose.
Conclusions: The hypertension doesn’t significantly increase the risk of PAD in patients with DM2.

REFERENCES

1. Shammas NW. Epidemiology, clasification, and modificable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007;3(2):229-234.

2. McDermott MM. The magnitude of the problem of peripheral arterial disease: Epidemiology and clinical significance. Am Fam Physician 2006;73 supp 4:S2-S7.

3. Gey DC, Lesho EP, Manngold J. Management of peripheral arterial disease. Am Fam Physician 2004;69:525-532.

4. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease. Morbidity and mortality implications. Circulation 2006;114:688-699.

5. Hirsch,AT, Haskal,ZJ, Hertzer,NR, et al: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. rculation 2006; 113(11):e463-e654.

6. White C. Intermittent Claudication. N Eng J Med 2007;356:1241-1250.

7. Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996;22(4):391-398.

8. Fowkes FG. The measurement of atheroesclerotic peripheral disease in epidemiological surveys. Int J Epidemiol 1988;17:248-254.

9. Feigelson HS, Criqui MH, Fronek A, Langer RD, Molgaard CA. Screening for peripheral arterial disease: the sensitivity, specificity and predictive value of noninvasive tests in a defined population. Am J Epidemiol 1994;140:526-534.

10. Nassoura ZE, Ivatury RR, Simon RJ. A reassessment of Doppler pressure indices in the detection of arterial lesions in proximity penetrating injuries of extremities: a prospective study. Am J Emerg Med 1996;14:151-156.

11. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C et al. Functional decline in peripheral arterial disease. Associations with the ankle brachial index and leg symptoms. JAMA 2004;292:453-461.

12. Shah DJ, Brown D, Kim RJ, Grizzard JD. Magnetic resonance evaluation of peripheral arterial disease. Cardiol Clin 2007;25:185-212.

13. Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006;98(suppl):59K-77K.

14. Stevens G, Díaz RH, Thomas KJ, Rivera JA, Carvalho N, Barquera S et al. Characterizing the epidemiological transition in Mexico: National and subnational burden of diseases, injuries and risks factors. PLoS Med 2008;5(8):e125.

15. Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelín-Hernández G, Grupo ENSA-2000, Attie F et al. Hipertensión arterial en México: Resultados de la encuesta nacional de salud (ENSA) 2000. Arch Cardiol Mex 2002;72:71-84.

16. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertense Res 1995;18:181-196.

17. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the national health and nutrition examination survey, 1999-2000. Circulation 2004;110:738-743.

18. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes. Circulation 2003;107:753-756.

19. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, MPH, Fabsitz RR et al. Relationship of high and low ankle brachial index to all-Cause and cardiovascular disease mortality the strong heart study. Circulation 2004;109:733-739.

20. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the national health and nutrition examination survey, 1999-2000. Circulation 2004;110:738-743.

21. Criqui MH, Longer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of ten years in patients with peripheral arterial disease. N Eng J Med 1992;326:381-386.